nach oben

Archives of Dermatological Research

Erschienen in:

01.07.2009 | Original Paper

Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis

verfasst von: Jose Antonio O’Daly, R. Lezama, J. Gleason

Erschienen in: Archives of Dermatological Research | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

A first generation polyvalent vaccine (AS100¹) was manufactured with protein from several cultured leishmania species, which proved to be effective in the treatment of psoriasis. To determine the effective factor, a single blind trial with four monovalent second generation vaccines (AS100²) was done in 26 subjects, which also resulted in remission of psoriasis. AS100² vaccines were further purified, resulting in seven chromatography fractions (AS200) per species. In vitro testing of the fractions on blood lymphocytes resulted in subjects being categorized as low or high responders before treatment. Both responder groups had no statistical difference in clinical outcome after AS100¹ treatment. Subsequently, a single-blind trial in 55 subjects treated with AS200 fractions from Leishmania brasiliensis also induced remission of Psoriasis. Two HIV ± subjects with plaque psoriasis experienced remission after treatment with AS100¹. There are factors in leishmania species which induce remission of psoriasis by stimulating lymphocytes.

Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL12, Il-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm 2005:273–279. doi:10.1155/MI.2005.273 CrossRef

Balagon MV, Tan PL, Prestidge R et al (2001) Improvement in psoriasis after intradermal administration of delipidated deglycolipidated Mycobacterium vaccae (PVAC) results of an open label trial. Clin Exp Dermatol 26:233–241. doi:10.1046/j.1365-2230.2001.00804.x PubMedCrossRef

Christophers E, Mrowietz U (2003) Psoriasis. In: Freedberg IM, Eisen AZ, Wolff KK, Austen F, Goldsmith LA, Katz SI (eds) Fitzpatrick’s dermatology in general medicine, 6th edn. McGraw-Hill, New York, pp 407–427

Dalbeth N, Yeoman S, Dockerty JL et al (2004) A randomized placebo controlled trial of delipidated deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis. Ann Rheum Dis 63:718–722. doi:10.1136/ard.2003.007104 PubMedCrossRef

Davies M (1983) Phase variations in the modulation of the immune response. Immunol Today 4:103–106. doi:10.1016/0167-5699(83)90016-6 CrossRef

Fredriksson T, Pettersson U (1978) Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157:238–244PubMedCrossRef

Ghoreschi K, Rocken M (2004) Immune deviation strategies in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 3:193–198. doi:10.2174/1568010043343949 PubMedCrossRef

Gudjonsson JE, Johnston A, Sigmundsdottir H et al (2004) Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 135:1–8. doi:10.1111/j.1365-2249.2004.02310.x PubMedCrossRef

Harvima IT, Nilsson G, Suttle MM et al (2008) Is there a role for mast cells in psoriasis? Arch Dermatol Res 300:461–478. doi:10.1007/s00403-008-0874-x PubMedCrossRef

10.

Hernadez-Pando R, Pavon L, Arriaga K et al (1997) Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 65:3317–3327

11.

Jariwala SP (2007) The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 299:359–366. doi:10.1007/s00403-007-0775-4 PubMedCrossRef

12.

Lehrer A, Bressanelli A, Wachsmann V et al (1998) Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 21:71–77. doi:10.1111/j.1574-695X.1998.tb01151.x PubMedCrossRef

13.

Lowry OH, Rosebrough NJ, Farr AL et al (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275PubMed

14.

Mahoney SE, Duvic M, Nickoloff BJ et al (1991) Immunodeficieny virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi’s sarcoma lesions. J Clin Invest 88:174–185. doi:10.1172/JCI115275 PubMedCrossRef

15.

Mallon E (2000) Retroviruses and psoriasis. Curr Opin Infect Dis 13:103–107PubMed

16.

Menter AM, Krueger GC, Feldman SR et al (2003) Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol 49(2):S39–S43. doi:10.1016/mjd.2003.545 PubMedCrossRef

17.

Nahary L, Tamarkin A, Kayam N et al (2008) An investigation of antistreptococcal antibody responses in gutatte psoriasis. Arch Dermatol Res 300:441–449. doi:10.1007/s00403-008-0866-x PubMedCrossRef

18.

Netto EM, Takahashi D, de Oliveira M et al (2006) Phase II randomized, placebo control trial of M. Vaccae-derived protein (PVAC) for the treatment of psoriasis. Vaccine 24:5056–5063. doi:10.1016/j.vaccine.2006.03.047 PubMedCrossRef

19.

O’Daly JA, Lezama R, Rodriguez PJ et al (2009) Antigens from Leishmania amastigotes induced clinical remission of psoriasis. Arch Dermatol Res 301:1–13. doi:10.1007/s00403-008-0883-9 PubMedCrossRef

20.

O’Daly JA, Cabrera Z (1986) Immunization of hamsters with TLCK-killed parasites induce protection against Leishmania infection. Acta Trop 43:225–236PubMed

21.

Reich K, Garbe C, Blaschke V et al (2001) Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocytes maturation. J Invest Dermatol 116:319–329. doi:10.1046/j.1523-1747.2001.01248.x PubMedCrossRef

22.

Seifert M, Sterry W, Effenberger E et al (2000) The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keratinocytes. Arch Dermatol Res 292:64–72. doi:10.1007/s004030050473 CrossRef

23.

Serrano LE, O’Daly JA (1987) Protein fraction from Trypanosoma cruzi infected spleen cell supernatants with immunosuppressive activity in vitro. Int J Parasitol 17:851–861. doi:10.1016/0020-7519(87)90069-5 PubMedCrossRef

24.

Sigmundsdottir H, Sigurgeirsson B, Toye-Blomberg M et al (1997) Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45:688–697. doi:10.1046/j.1365-3083.1997.d01-438.x PubMedCrossRef

25.

Skinner MA, Prestidge R, Yuan S et al (2001) The ability of heat-killed Mycobacterium vaccae to stimulate a cytotoxic T-cell response to an unrelated protein is associated with a 65 kilodalton heat-shock protein. Immunology 102:225–233PubMedCrossRef

26.

Skinner MA, Yuan S, Prestidge R et al (1997) Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 65:4525–4530PubMed

27.

Smith PK, Krohn RI, Hermanson GT et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85. doi:10.1016/0003-2697(85)90442-7 PubMedCrossRef

28.

Sokal JE (1975) Measurement of delayed skin test responses. N Engl J Med 293:501–502PubMed

29.

Stratis A, Pasparakis M, Rupec RA et al (2006) Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 116:2094–2104. doi:10.1172/JCI27179 PubMedCrossRef

30.

Wang H, Peters T, Kess D et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105–2114. doi:10.1172/JCI27180 PubMedCrossRef

Titel: Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis
verfasst von: Jose Antonio O’Daly
R. Lezama
J. Gleason
Publikationsdatum: 01.07.2009
Verlag: Springer-Verlag
Erschienen in: Archives of Dermatological Research / Ausgabe 6/2009
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-009-0940-z

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis

Abstract

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Update Dermatologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2009

Matrix metalloproteinase-2 promoter variability in psoriasis

The serotonin transporter protein is expressed in psoriasis, where it may play a role in regulating apoptosis

Therapeutic effects of heme oxygenase-1 on psoriasiform skin lesions in guinea pigs

Osteopontin: a new emerging role in psoriasis

Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab

Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

So sicher sind Tattoos: Neue Daten zur Risikobewertung

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Update Dermatologie